Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury
We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associate...
Gespeichert in:
| Veröffentlicht in: | Neuropsychopharmacology (New York, N.Y.) N.Y.), 2016-04, Vol.41 (5), p.1191-1198 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1198 |
|---|---|
| container_issue | 5 |
| container_start_page | 1191 |
| container_title | Neuropsychopharmacology (New York, N.Y.) |
| container_volume | 41 |
| creator | McAllister, Thomas W Zafonte, Ross Jain, Sonia Flashman, Laura A George, Mark S Grant, Gerald A He, Feng Lohr, James B Andaluz, Norberto Summerall, Lanier Paulus, Martin P Raman, Rema Stein, Murray B |
| description | We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods. |
| doi_str_mv | 10.1038/npp.2015.282 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4793116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1772834513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-fb7f5fee4b1d542554b33cdfb74b8373d4fa7050d5df8e86d47787756c2a02173</originalsourceid><addsrcrecordid>eNqNkkFvFCEYhonR2O3Wm2dD4sWDs4WBAfZiUte2Nqnpxq5Jb4QZmC6bGZgC02b9Rf7MstnaqCdPBHh48n0fLwBvMZphRMSxG4ZZiXA1K0X5Akwwp6hghN68BBMk5qTAhNwcgMMYNyhTnInX4KBkhGHE0AT8-q6c9r39aTRcdqoxtS8W3qXguy4frYJVHfQt_GbSetsNa-OsVslAH-C56pRLqrfOwDbvlyZEG5NxCZ72Plnv8tNshwt_62yy9wZeb_sh-T7Ckxh9Y7NIwweb1nC5uv6yY4-zZxXU2KtkG_g5KOvghduMYXsEXrWqi-bN0zoFP85OV4uvxeXV-cXi5LJoKBepaGveVq0xtMa6omVV0ZqQRudjWgvCiaat4qhCutKtMIJpyrngvGJNqVCJOZmCT3vvMNa90U1uJ6hODsH2KmylV1b-fePsWt76e0n5nGDMsuDDkyD4u9HEJHsbG9PlYRk_Rok5Z4wShPH_oKUgtMpfOAXv_0E3fgx5wnsKsznnu-I_7qkm-BiDaZ_rxkju0iJzWuQuLTKnJePv_uz1Gf4dD_II-Wa-tA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1772169777</pqid></control><display><type>article</type><title>Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>McAllister, Thomas W ; Zafonte, Ross ; Jain, Sonia ; Flashman, Laura A ; George, Mark S ; Grant, Gerald A ; He, Feng ; Lohr, James B ; Andaluz, Norberto ; Summerall, Lanier ; Paulus, Martin P ; Raman, Rema ; Stein, Murray B</creator><creatorcontrib>McAllister, Thomas W ; Zafonte, Ross ; Jain, Sonia ; Flashman, Laura A ; George, Mark S ; Grant, Gerald A ; He, Feng ; Lohr, James B ; Andaluz, Norberto ; Summerall, Lanier ; Paulus, Martin P ; Raman, Rema ; Stein, Murray B</creatorcontrib><description>We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.</description><identifier>ISSN: 0893-133X</identifier><identifier>EISSN: 1740-634X</identifier><identifier>DOI: 10.1038/npp.2015.282</identifier><identifier>PMID: 26361060</identifier><identifier>CODEN: NEROEW</identifier><language>eng</language><publisher>England: Nature Publishing Group</publisher><subject>Adult ; Affective Symptoms - drug therapy ; Affective Symptoms - etiology ; Alzheimer's disease ; Brain Injuries, Traumatic - complications ; Brain Injuries, Traumatic - drug therapy ; Brain Injuries, Traumatic - psychology ; Brain research ; Cognition Disorders - drug therapy ; Cognition Disorders - etiology ; Dopamine ; Double-Blind Method ; Female ; Galantamine - therapeutic use ; Hospitals ; Humans ; Male ; Medicine ; Memory ; Methylphenidate - therapeutic use ; Middle Aged ; Neuropsychological Tests ; Neurosurgery ; Original ; Pilot Projects ; Post traumatic stress disorder ; Psychiatry ; Public health ; Stress Disorders, Post-Traumatic - complications ; Stress Disorders, Post-Traumatic - drug therapy ; Stress Disorders, Post-Traumatic - psychology ; Traumatic brain injury ; Treatment Outcome</subject><ispartof>Neuropsychopharmacology (New York, N.Y.), 2016-04, Vol.41 (5), p.1191-1198</ispartof><rights>Copyright Nature Publishing Group Apr 2016</rights><rights>Copyright © 2016 American College of Neuropsychopharmacology 2016 American College of Neuropsychopharmacology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-fb7f5fee4b1d542554b33cdfb74b8373d4fa7050d5df8e86d47787756c2a02173</citedby><cites>FETCH-LOGICAL-c478t-fb7f5fee4b1d542554b33cdfb74b8373d4fa7050d5df8e86d47787756c2a02173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793116/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4793116/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26361060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McAllister, Thomas W</creatorcontrib><creatorcontrib>Zafonte, Ross</creatorcontrib><creatorcontrib>Jain, Sonia</creatorcontrib><creatorcontrib>Flashman, Laura A</creatorcontrib><creatorcontrib>George, Mark S</creatorcontrib><creatorcontrib>Grant, Gerald A</creatorcontrib><creatorcontrib>He, Feng</creatorcontrib><creatorcontrib>Lohr, James B</creatorcontrib><creatorcontrib>Andaluz, Norberto</creatorcontrib><creatorcontrib>Summerall, Lanier</creatorcontrib><creatorcontrib>Paulus, Martin P</creatorcontrib><creatorcontrib>Raman, Rema</creatorcontrib><creatorcontrib>Stein, Murray B</creatorcontrib><title>Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury</title><title>Neuropsychopharmacology (New York, N.Y.)</title><addtitle>Neuropsychopharmacology</addtitle><description>We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.</description><subject>Adult</subject><subject>Affective Symptoms - drug therapy</subject><subject>Affective Symptoms - etiology</subject><subject>Alzheimer's disease</subject><subject>Brain Injuries, Traumatic - complications</subject><subject>Brain Injuries, Traumatic - drug therapy</subject><subject>Brain Injuries, Traumatic - psychology</subject><subject>Brain research</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - etiology</subject><subject>Dopamine</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Galantamine - therapeutic use</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Memory</subject><subject>Methylphenidate - therapeutic use</subject><subject>Middle Aged</subject><subject>Neuropsychological Tests</subject><subject>Neurosurgery</subject><subject>Original</subject><subject>Pilot Projects</subject><subject>Post traumatic stress disorder</subject><subject>Psychiatry</subject><subject>Public health</subject><subject>Stress Disorders, Post-Traumatic - complications</subject><subject>Stress Disorders, Post-Traumatic - drug therapy</subject><subject>Stress Disorders, Post-Traumatic - psychology</subject><subject>Traumatic brain injury</subject><subject>Treatment Outcome</subject><issn>0893-133X</issn><issn>1740-634X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkkFvFCEYhonR2O3Wm2dD4sWDs4WBAfZiUte2Nqnpxq5Jb4QZmC6bGZgC02b9Rf7MstnaqCdPBHh48n0fLwBvMZphRMSxG4ZZiXA1K0X5Akwwp6hghN68BBMk5qTAhNwcgMMYNyhTnInX4KBkhGHE0AT8-q6c9r39aTRcdqoxtS8W3qXguy4frYJVHfQt_GbSetsNa-OsVslAH-C56pRLqrfOwDbvlyZEG5NxCZ72Plnv8tNshwt_62yy9wZeb_sh-T7Ckxh9Y7NIwweb1nC5uv6yY4-zZxXU2KtkG_g5KOvghduMYXsEXrWqi-bN0zoFP85OV4uvxeXV-cXi5LJoKBepaGveVq0xtMa6omVV0ZqQRudjWgvCiaat4qhCutKtMIJpyrngvGJNqVCJOZmCT3vvMNa90U1uJ6hODsH2KmylV1b-fePsWt76e0n5nGDMsuDDkyD4u9HEJHsbG9PlYRk_Rok5Z4wShPH_oKUgtMpfOAXv_0E3fgx5wnsKsznnu-I_7qkm-BiDaZ_rxkju0iJzWuQuLTKnJePv_uz1Gf4dD_II-Wa-tA</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>McAllister, Thomas W</creator><creator>Zafonte, Ross</creator><creator>Jain, Sonia</creator><creator>Flashman, Laura A</creator><creator>George, Mark S</creator><creator>Grant, Gerald A</creator><creator>He, Feng</creator><creator>Lohr, James B</creator><creator>Andaluz, Norberto</creator><creator>Summerall, Lanier</creator><creator>Paulus, Martin P</creator><creator>Raman, Rema</creator><creator>Stein, Murray B</creator><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160401</creationdate><title>Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury</title><author>McAllister, Thomas W ; Zafonte, Ross ; Jain, Sonia ; Flashman, Laura A ; George, Mark S ; Grant, Gerald A ; He, Feng ; Lohr, James B ; Andaluz, Norberto ; Summerall, Lanier ; Paulus, Martin P ; Raman, Rema ; Stein, Murray B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-fb7f5fee4b1d542554b33cdfb74b8373d4fa7050d5df8e86d47787756c2a02173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Affective Symptoms - drug therapy</topic><topic>Affective Symptoms - etiology</topic><topic>Alzheimer's disease</topic><topic>Brain Injuries, Traumatic - complications</topic><topic>Brain Injuries, Traumatic - drug therapy</topic><topic>Brain Injuries, Traumatic - psychology</topic><topic>Brain research</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - etiology</topic><topic>Dopamine</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Galantamine - therapeutic use</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Memory</topic><topic>Methylphenidate - therapeutic use</topic><topic>Middle Aged</topic><topic>Neuropsychological Tests</topic><topic>Neurosurgery</topic><topic>Original</topic><topic>Pilot Projects</topic><topic>Post traumatic stress disorder</topic><topic>Psychiatry</topic><topic>Public health</topic><topic>Stress Disorders, Post-Traumatic - complications</topic><topic>Stress Disorders, Post-Traumatic - drug therapy</topic><topic>Stress Disorders, Post-Traumatic - psychology</topic><topic>Traumatic brain injury</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McAllister, Thomas W</creatorcontrib><creatorcontrib>Zafonte, Ross</creatorcontrib><creatorcontrib>Jain, Sonia</creatorcontrib><creatorcontrib>Flashman, Laura A</creatorcontrib><creatorcontrib>George, Mark S</creatorcontrib><creatorcontrib>Grant, Gerald A</creatorcontrib><creatorcontrib>He, Feng</creatorcontrib><creatorcontrib>Lohr, James B</creatorcontrib><creatorcontrib>Andaluz, Norberto</creatorcontrib><creatorcontrib>Summerall, Lanier</creatorcontrib><creatorcontrib>Paulus, Martin P</creatorcontrib><creatorcontrib>Raman, Rema</creatorcontrib><creatorcontrib>Stein, Murray B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McAllister, Thomas W</au><au>Zafonte, Ross</au><au>Jain, Sonia</au><au>Flashman, Laura A</au><au>George, Mark S</au><au>Grant, Gerald A</au><au>He, Feng</au><au>Lohr, James B</au><au>Andaluz, Norberto</au><au>Summerall, Lanier</au><au>Paulus, Martin P</au><au>Raman, Rema</au><au>Stein, Murray B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury</atitle><jtitle>Neuropsychopharmacology (New York, N.Y.)</jtitle><addtitle>Neuropsychopharmacology</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>41</volume><issue>5</issue><spage>1191</spage><epage>1198</epage><pages>1191-1198</pages><issn>0893-133X</issn><eissn>1740-634X</eissn><coden>NEROEW</coden><abstract>We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.</abstract><cop>England</cop><pub>Nature Publishing Group</pub><pmid>26361060</pmid><doi>10.1038/npp.2015.282</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-133X |
| ispartof | Neuropsychopharmacology (New York, N.Y.), 2016-04, Vol.41 (5), p.1191-1198 |
| issn | 0893-133X 1740-634X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4793116 |
| source | MEDLINE; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Affective Symptoms - drug therapy Affective Symptoms - etiology Alzheimer's disease Brain Injuries, Traumatic - complications Brain Injuries, Traumatic - drug therapy Brain Injuries, Traumatic - psychology Brain research Cognition Disorders - drug therapy Cognition Disorders - etiology Dopamine Double-Blind Method Female Galantamine - therapeutic use Hospitals Humans Male Medicine Memory Methylphenidate - therapeutic use Middle Aged Neuropsychological Tests Neurosurgery Original Pilot Projects Post traumatic stress disorder Psychiatry Public health Stress Disorders, Post-Traumatic - complications Stress Disorders, Post-Traumatic - drug therapy Stress Disorders, Post-Traumatic - psychology Traumatic brain injury Treatment Outcome |
| title | Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A32%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomized%20Placebo-Controlled%20Trial%20of%20Methylphenidate%20or%20Galantamine%20for%20Persistent%20Emotional%20and%20Cognitive%20Symptoms%20Associated%20with%20PTSD%20and/or%20Traumatic%20Brain%20Injury&rft.jtitle=Neuropsychopharmacology%20(New%20York,%20N.Y.)&rft.au=McAllister,%20Thomas%20W&rft.date=2016-04-01&rft.volume=41&rft.issue=5&rft.spage=1191&rft.epage=1198&rft.pages=1191-1198&rft.issn=0893-133X&rft.eissn=1740-634X&rft.coden=NEROEW&rft_id=info:doi/10.1038/npp.2015.282&rft_dat=%3Cproquest_pubme%3E1772834513%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1772169777&rft_id=info:pmid/26361060&rfr_iscdi=true |